Aclaris Therapeutics FY Conference Summary Company Overview - Aclaris Therapeutics is a clinical-stage biotech company focused on discovering and developing therapeutics for inflammatory and immunological conditions. The leadership team has extensive experience in drug development from companies like MedImmune, AZ, Centocor, J&J, GSK, and Pfizer [2][4]. Clinical Pipeline - Aclaris has three clinical-stage programs, including: - **Bosakitug**: An anti-TSLP monoclonal antibody completing a Phase II study in atopic dermatitis (AD) in 2026 [2][4]. - **ATI-052**: A bispecific antibody targeting TSLP and IL-4, with ongoing Phase I studies [3][12]. - **ATI-2138**: A potent ITK inhibitor combined with JAK3, with plans for further clinical trials [3][48]. Key Data and Results - **Bosakitug**: - Demonstrated a 90% EASI-75 response in a proof-of-concept study and over 80% responders in IJ01 [6]. - Retention time of 400 hours, significantly longer than competitors like tezepelumab [5][6]. - Expected to show top-line results by the end of 2026 [10]. - **ATI-052**: - Phase I study showed a 26-day half-life, three times longer than dupilumab [18]. - Demonstrated four times more potency than the combination of Tezspire and dupilumab in inhibiting TSLP IL-4-activated PBMC populations [19]. - Safety profile was favorable, with no significant adverse events reported [20]. - **ATI-2138**: - Focused on indications with less competition from existing JAK inhibitors, such as alopecia [46][47]. - Preclinical data showed promising results in severe models of alopecia [47]. Future Plans and Expectations - Aclaris plans to submit an IND for ATI-9494 by the end of the year [48]. - The company is optimistic about the potential of its programs, with data expected in the second half of the year for both bosakitug and ATI-052 [34][38]. - The company aims to explore additional indications for its therapies based on the outcomes of ongoing studies [11][42]. Market Position and Competitive Landscape - Aclaris believes its therapies could offer advantages over existing treatments like dupilumab, particularly in dosing frequency and targeting broader patient populations [38][39]. - The company is positioning itself to capitalize on the growing market for treatments in atopic dermatitis and asthma, with a focus on both T2 high and T2 low patient populations [26][39]. Conclusion - Aclaris Therapeutics is poised for significant developments in 2026, with multiple clinical trials underway and promising data expected. The company is strategically targeting unmet medical needs in the inflammatory and immunological space, with a strong emphasis on safety and efficacy in its drug development efforts [4][51].

Core Insights - Aclaris Therapeutics reported positive interim results from its Phase 1a trials for the bispecific antibody ATI-052, indicating strong safety and tolerability, with complete results expected in Q2 2026 [1][3] - The company has initiated Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma, with top line results anticipated in the second half of 2026 [1][2] - Aclaris plans to file an Investigational New Drug (IND) application for its lead ITK inhibitor candidate, ATI-9494, in the second half of 2026 [1][12] Pipeline Developments - Positive interim results from the Phase 1a SAD/MAD trial of ATI-052 showed a favorable safety profile and robust target engagement, supporting potential extended dosing every three months [3][2] - Two Phase 1b POC trials for ATI-052 have been initiated, with results expected in the latter half of 2026 [3][2] - Planning for a Phase 2b program for ATI-052 is underway, targeting asthma and atopic dermatitis as initial indications [3] Financial Performance - Aclaris reported a net loss of $19.8 million for Q4 2025, a significant decrease from a net loss of $96.6 million in Q4 2024 [7] - Total revenue for Q4 2025 was $1.3 million, down from $9.2 million in Q4 2024, primarily due to a prior commercial milestone [8] - Research and development expenses increased to $16.6 million in Q4 2025 from $9.0 million in the prior year, driven by higher costs associated with product candidate development [9] Liquidity and Capital Resources - As of December 31, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $151.4 million, down from $203.9 million in 2024 [6][20] - The company believes its current financial resources will be sufficient to fund operations into the second half of 2028 [6]